Skip to Content

Vanderbilt-Ingram Cancer CenterVanderbilt-Ingram Cancer Center

 

BMT Outcome Data

Assuring quality of care and the best possible outcomes for your patients is also an important commitment. We conduct quarterly assessment of core quality indicators, including engraftment and 100-day mortality and conduct monthly quality assurance meetings with representatives from each aspect of the transplant process.

Outcomes by type of transplant

Autologous transplants

  • Total number of patients in 2007: 64
    100-day survival rate: 95%
  • Total number of patients 2004-2006: 250
    100-day survival rate: 96%
    One-year survival: 86%
  • More Details by Disease (PDF format)

Allogeneic Myeloablative Related Donor Transplants
0-1 Antigen Mismatch

  • Total patients in 2007: 14
    100-day survival rate: 93%
  • Total patients 2004-2006: 53
    100-day survival rate: 91%
    One-year survival rate: 68%
  • More Details by Disease (PDF format)

Allogeneic Non-myeloablative Related Donor Transplant
0-1 Antigen Mismatch

  • Total patients in 2007: 13
    100-day survival rate: 100%
  • Total patients 2004-2006: 38
    100-day survival rate: 92%
    One-year survival rate: 63%
  • More Details by Disease (PDF format)

Note: Vanderbilt-Ingram Cancer Center does not perform allogeneic myeloablative transplants involving related donors with a greater than 1 antigen mismatch.

Allogeneic Unrelated Donor Transplants

  • Total patients in 2007: 15
    100-day survival rate: 100%
  • Total patients 2004-2006: 37
    100-day survival rate: 86%
    One-year survival rate: 62%
  • More Details by Disease (PDF format)

Allogeneic Non-myeloablative Unrelated Donor Transplants

  • Total patients in 2007: 12
    100-day survival rate: 67%
  • Total patients 2004-2006: 23
    100-day survival rate: 70%
    One-year survival rate: 39%
  • More Details by Disease (PDF format)

Allogeneic Cord Blood (both related and unrelated)

  • Total patients in 2007: 3
    100-day survival rate: 100%
  • Total patients 2004-2006: 5
    100-day survival rate: 80%
    One-year survival rate: 40%
  • More Details by Disease (PDF format)